X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Summary

To assess treatment effectiveness and safety of oral X-396 capsule (Ensartinib) administered to Chinese patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a c-ROS Oncogene (ROS1) positive gene mutation (translocation or inversion).

Timeline

Start

2018-06-15

Primary completion

2020-03

Completion

2020-09

Drugs

Indications